KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Leases (2019 - 2025)

Pacira BioSciences has reported Current Leases over the past 7 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Current Leases at $9.8 million for Q4 2025, up 10.71% from a year ago — trailing twelve months through Dec 2025 was $9.8 million (up 10.71% YoY), and the annual figure for FY2025 was $9.8 million, up 10.71%.
  • Current Leases for Q4 2025 was $9.8 million at Pacira BioSciences, up from $9.7 million in the prior quarter.
  • Over the last five years, Current Leases for PCRX hit a ceiling of $9.8 million in Q4 2025 and a floor of $5.5 million in Q1 2021.
  • Median Current Leases over the past 5 years was $8.9 million (2023), compared with a mean of $8.4 million.
  • Biggest five-year swings in Current Leases: dropped 25.93% in 2021 and later surged 45.7% in 2022.
  • Pacira BioSciences' Current Leases stood at $7.9 million in 2021, then increased by 15.59% to $9.1 million in 2022, then dropped by 3.51% to $8.8 million in 2023, then rose by 0.98% to $8.9 million in 2024, then grew by 10.71% to $9.8 million in 2025.
  • The last three reported values for Current Leases were $9.8 million (Q4 2025), $9.7 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.